سعر نوفيبرا 67مجم 20 كبسول 2022

Nofibra 67 mg 20 capsules (Pharo Pharma, Egypt): fenofibrate 67 mg oral capsules, a fibrate lipid-lowering agent; box of 20 capsules.

• Adjunct to diet: severe hypertriglyceridaemia with or without low HDL-C; mixed hyperlipidaemia when a statin is contraindicated or not tolerated; mixed hyperlipidaemia at high CV risk in addition to a statin when TG and HDL-C are not adequately controlled.Population: Adults (not recommended under 18 years)DailyMed (U.S. National Library of Medicine)
• Adjunct to diet for reduction of LDL-C, total-C, triglycerides and Apo B in adults with primary hypercholesterolaemia or mixed dyslipidaemia (Fredrickson IIa/IIb); adjunct to diet for adults with hypertriglyceridaemia (Fredrickson IV and V).Population: AdultsDailyMed (U.S. National Library of Medicine)

• In placebo-controlled trials adverse events led to discontinuation in 5% of fenofibrate-treated patients (3% placebo); increased liver function tests were the most frequent reason; photosensitivity reactions reported; other events included abdominal pain and back pain.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Hepatic insufficiency (including biliary cirrhosis and unexplained persistent liver function abnormality); known gallbladder disease; severe renal insufficiency (eGFR < 30); chronic or acute pancreatitis (except acute pancreatitis due to severe hypertriglyceridaemia); known photoallergy or phototoxic reaction with fibrates or ketoprofen; hypersensitivity.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Hypersensitivity to fenofibrate; hepatic or severe renal dysfunction including primary biliary cirrhosis and unexplained persistent liver function abnormality; pre-existing gallbladder disease.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Monitor transaminases every 3 months during the first 12 months then periodically; discontinue if AST/ALT exceed 3 x ULN or hepatitis is confirmed; pancreatitis reported; muscle toxicity including rare rhabdomyolysis (risk increased by hypoalbuminaemia and previous renal insufficiency); treat secondary causes of hyperlipidaemia first.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Serious drug-induced liver injury (including liver transplantation and death) reported postmarketing; monitor ALT, AST and total bilirubin at baseline and periodically and discontinue if liver injury develops; cholelithiasis (discontinue if gallstones found); caution with oral anticoagulants.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Coumarin anticoagulantsPotentiates coumarin-type anticoagulants (prolonged prothrombin time/INR); reduce anticoagulant dosage and check INR frequently until stable.DailyMed (U.S. National Library of Medicine)
• HMG-CoA reductase inhibitors (statins)Avoid combined use unless the lipid benefit outweighs the increased risk of myopathy, rhabdomyolysis and acute renal failure.DailyMed (U.S. National Library of Medicine)
• Bile acid sequestrants (resins)Take fenofibrate at least 1 hour before or 4-6 hours after a bile acid binding resin.DailyMed (U.S. National Library of Medicine)

• Safety in pregnant women has not been established; no adequate and well-controlled studies; use during pregnancy only if the potential benefit justifies the potential risk to the fetus.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Not known whether fenofibrate is excreted into milk; decide whether to discontinue nursing or the drug.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Fenofibrate: Prodrug hydrolysed to fenofibric acid, which activates PPAR-alpha, increasing lipolysis and elimination of triglyceride-rich particles and reducing apoprotein C-III.